<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003967</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067168</org_study_id>
    <secondary_id>GOG-9807</secondary_id>
    <nct_id>NCT00003967</nct_id>
  </id_info>
  <brief_title>Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer</brief_title>
  <official_title>A Phase I Study of Sequential Prolonged Oral Topotecan (IND# 58,131) and Prolonged Oral Etoposide as Second Line Therapy in Ovarian, Peritoneal or Tubal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>GOG Foundation</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of topotecan plus etoposide in treating&#xD;
      patients who have recurrent ovarian cancer, peritoneal cancer, or fallopian tube cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose of sequential prolonged topotecan and&#xD;
      prolonged etoposide as second line therapy in patients with recurrent ovarian epithelial,&#xD;
      peritoneal, or tubal cancer. II. Determine the nature and degree of toxicity of this&#xD;
      treatment regimen in this patient population. III. Evaluate the response rate and time to&#xD;
      disease progression in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study. Patients receive oral topotecan daily on days 1-5&#xD;
      and oral etoposide daily on days 8-10. Courses repeat every 28 days in the absence of disease&#xD;
      progression or unacceptable side effects. Patients achieving partial or complete response or&#xD;
      stable disease continue treatment for at least 4-6 courses. Cohorts of 3-6 patients receive&#xD;
      topotecan and etoposide on increasing numbers of days until the maximum tolerated dose (MTD)&#xD;
      is determined. The MTD is defined as the dose at which no greater than 1 of 6 patients&#xD;
      experiences dose limiting toxicity. Patients are followed every 3 months or until death.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study within 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1999</start_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed ovarian epithelial, peritoneal, or tubal&#xD;
        cancer Epithelial cell types Serous adenocarcinoma Endometrioid adenocarcinoma Mucinous&#xD;
        adenocarcinoma Undifferentiated carcinoma Clear cell adenocarcinoma Mixed epithelial&#xD;
        carcinoma Transitional cell Malignant Brenner's tumor Adenocarcinoma not otherwise&#xD;
        specified Measurable or evaluable disease No brain or leptomeningeal metastases No&#xD;
        symptomatic bowel involvement of ovarian cancer Not eligible for higher priority GOG phase&#xD;
        II or III study&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: GOG 0-2 Life expectancy: Not&#xD;
        specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at&#xD;
        least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times normal SGOT/SGPT/GGT no&#xD;
        greater than 3 times normal Alkaline phosphatase no greater than 3 times normal No acute&#xD;
        hepatitis Renal: Creatinine no greater than 2.0 mg/dL OR Creatinine clearance greater than&#xD;
        50 mL/min Other: No septicemia or severe infection Body surface area at least 1 m2 Adequate&#xD;
        intestinal function (i.e., does not require IV hydration or nutritional support) Not&#xD;
        pregnant or nursing Negative pregnancy test Fertile patients must use effective&#xD;
        contraception 3 months prior to and during study No other malignancies within the past 5&#xD;
        years except curatively treated skin cancer No other severe medical problems that would&#xD;
        prevent compliance No condition of the GI tract that would affect GI absorption and&#xD;
        motility No severe gastrointestinal bleeding&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No&#xD;
        prior topotecan, other camptothecin analogs, or etoposide At least 1 prior&#xD;
        cisplatin/paclitaxel based regimen At least 3 weeks since prior chemotherapy and recovered&#xD;
        No more than 2 prior cytotoxic chemotherapy regimens No other concurrent chemotherapy&#xD;
        Endocrine therapy: No concurrent hormonal therapy for cancer Radiotherapy: At least 3 weeks&#xD;
        since prior radiotherapy to no more than 10% of the bone marrow and recovered No concurrent&#xD;
        radiotherapy Surgery: Not specified Other: At least 28 days or 5 half lives since prior&#xD;
        investigational drugs (including cytotoxic drugs) No concurrent metoclopramide or cisapride&#xD;
        for maintaining gastric motility or emptying No chronic H2 antagonists, proton pump&#xD;
        inhibitors, or antacids for gastritis, gastroesophageal reflux disease, or gastric or&#xD;
        duodenal ulcers Intermittent antacids allowed, if no antacids 6 hours prior to and 90&#xD;
        minutes after topotecan&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter G. Rose, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at The University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center, Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper Hospital/University Medical Center</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital - Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rose PG, Markman M, Bell JG, Fusco NL. Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study. Gynecol Oncol. 2006 Aug;102(2):236-9. doi: 10.1016/j.ygyno.2005.12.003. Epub 2006 Jan 18.</citation>
    <PMID>16412499</PMID>
  </results_reference>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>March 30, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2004</study_first_posted>
  <last_update_submitted>May 24, 2013</last_update_submitted>
  <last_update_submitted_qc>May 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2013</last_update_posted>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>ovarian undifferentiated adenocarcinoma</keyword>
  <keyword>ovarian mixed epithelial carcinoma</keyword>
  <keyword>ovarian serous cystadenocarcinoma</keyword>
  <keyword>ovarian mucinous cystadenocarcinoma</keyword>
  <keyword>ovarian endometrioid adenocarcinoma</keyword>
  <keyword>ovarian clear cell cystadenocarcinoma</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <keyword>Brenner tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

